[go: up one dir, main page]

ITMI951649A0 - Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato - Google Patents

Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato

Info

Publication number
ITMI951649A0
ITMI951649A0 ITMI951649A ITMI951649A ITMI951649A0 IT MI951649 A0 ITMI951649 A0 IT MI951649A0 IT MI951649 A ITMI951649 A IT MI951649A IT MI951649 A ITMI951649 A IT MI951649A IT MI951649 A0 ITMI951649 A0 IT MI951649A0
Authority
IT
Italy
Prior art keywords
purine
antagonists
receptors
prevention
glutamate cytotoxicity
Prior art date
Application number
ITMI951649A
Other languages
English (en)
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of ITMI951649A0 publication Critical patent/ITMI951649A0/it
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Priority to IT95MI001649A priority Critical patent/IT1277373B1/it
Priority to IL12291596A priority patent/IL122915A/xx
Priority to ES96927588T priority patent/ES2173307T3/es
Priority to CA002224293A priority patent/CA2224293A1/en
Priority to HK99100850.1A priority patent/HK1015698B/xx
Priority to PCT/EP1996/003254 priority patent/WO1997004760A1/en
Priority to BR9609856A priority patent/BR9609856A/pt
Priority to RU98103500/14A priority patent/RU2211707C2/ru
Priority to US09/000,403 priority patent/US6326370B1/en
Priority to DE69621022T priority patent/DE69621022T2/de
Priority to DK96927588T priority patent/DK0841907T3/da
Priority to EP96927588A priority patent/EP0841907B1/en
Priority to JP9507214A priority patent/JPH11511126A/ja
Priority to AT96927588T priority patent/ATE216878T1/de
Priority to AU67366/96A priority patent/AU707808B2/en
Publication of ITMI951649A1 publication Critical patent/ITMI951649A1/it
Application granted granted Critical
Publication of IT1277373B1 publication Critical patent/IT1277373B1/it
Priority to US09/987,075 priority patent/US20020028790A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
IT95MI001649A 1995-07-28 1995-07-28 Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato IT1277373B1 (it)

Priority Applications (16)

Application Number Priority Date Filing Date Title
IT95MI001649A IT1277373B1 (it) 1995-07-28 1995-07-28 Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato
US09/000,403 US6326370B1 (en) 1995-07-28 1996-07-24 Use of agonists or antagonists of P2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
DK96927588T DK0841907T3 (da) 1995-07-28 1996-07-24 Anvendelse af agonister eller antagonister for P2 purinreceptorer til forebyggelse af glutamatfremkaldt cytotoksicitet
CA002224293A CA2224293A1 (en) 1995-07-28 1996-07-24 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
HK99100850.1A HK1015698B (en) 1995-07-28 1996-07-24 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
PCT/EP1996/003254 WO1997004760A1 (en) 1995-07-28 1996-07-24 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
BR9609856A BR9609856A (pt) 1995-07-28 1996-07-24 Compostos agonistas ou antagonistas de purinoceptores P2 uso dos mesmos e composição farmacológica
RU98103500/14A RU2211707C2 (ru) 1995-07-28 1996-07-24 Применение агонистов или антагонистов p2-пуриноцепторов для предупреждения цитотоксичности, вызываемой глютаматом
IL12291596A IL122915A (en) 1995-07-28 1996-07-24 Agonists and antagonists of p2 purinoceptor for use in the prevention of glutamate-evoked cytotoxicity and pharmaceutical compositions containing said agonist or antagonist
DE69621022T DE69621022T2 (de) 1995-07-28 1996-07-24 Verwendung von agonisten oder antagonisten der p2 purinozeptoren zur vermeidung der durch glutamat bedingten zytotoxizitaet
ES96927588T ES2173307T3 (es) 1995-07-28 1996-07-24 Utilizacion de agonistas o antigonistas de los purinoreceptores p2 para la citotoxicidad provocada por el glutamato.
EP96927588A EP0841907B1 (en) 1995-07-28 1996-07-24 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
JP9507214A JPH11511126A (ja) 1995-07-28 1996-07-24 グルタメートにより誘発される細胞毒性の防止のためのｐ▲下２▼プリノセプターの作動薬または拮抗薬の使用
AT96927588T ATE216878T1 (de) 1995-07-28 1996-07-24 Verwendung von agonisten oder antagonisten der p2 purinozeptoren zur vermeidung der durch glutamat bedingten zytotoxizitaet
AU67366/96A AU707808B2 (en) 1995-07-28 1996-07-24 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
US09/987,075 US20020028790A1 (en) 1995-07-28 2001-11-13 Use of agonists or antagonists of P2 purinoceptors for the prevention glutamate-evoked cytotoxicity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95MI001649A IT1277373B1 (it) 1995-07-28 1995-07-28 Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato

Publications (3)

Publication Number Publication Date
ITMI951649A0 true ITMI951649A0 (it) 1995-07-27
ITMI951649A1 ITMI951649A1 (it) 1997-01-27
IT1277373B1 IT1277373B1 (it) 1997-11-10

Family

ID=11372076

Family Applications (1)

Application Number Title Priority Date Filing Date
IT95MI001649A IT1277373B1 (it) 1995-07-28 1995-07-28 Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato

Country Status (14)

Country Link
US (2) US6326370B1 (it)
EP (1) EP0841907B1 (it)
JP (1) JPH11511126A (it)
AT (1) ATE216878T1 (it)
AU (1) AU707808B2 (it)
BR (1) BR9609856A (it)
CA (1) CA2224293A1 (it)
DE (1) DE69621022T2 (it)
DK (1) DK0841907T3 (it)
ES (1) ES2173307T3 (it)
IL (1) IL122915A (it)
IT (1) IT1277373B1 (it)
RU (1) RU2211707C2 (it)
WO (1) WO1997004760A1 (it)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615202D0 (en) * 1996-07-19 1996-09-04 Smithkline Beecham Plc Pharmaceuticals
SE9702002D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6462028B2 (en) * 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
IT1303815B1 (it) * 1998-12-02 2001-02-23 Consiglio Nazionale Ricerche Impiego di selettivi composti modulatori dei recettori purinici p2 perla prevenzione dei danni e della mortalita' causata da ischemia
US7141511B2 (en) * 2004-04-27 2006-11-28 Micron Technology Inc. Method and apparatus for fabricating a memory device with a dielectric etch stop layer
GB0520405D0 (en) * 2005-10-07 2005-11-16 Imp College Innovations Ltd Biological agents and method
EP3323415A1 (en) * 2016-11-16 2018-05-23 Institut du Cerveau et de la Moelle Epiniere-ICM Treatment of neurodegenerative diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4230493A1 (de) * 1992-09-11 1994-03-17 Institut Fuer Bioanalytik Gmbh Arzneimittel zur Behandlung des zentralen Nervensystems

Also Published As

Publication number Publication date
DK0841907T3 (da) 2002-07-15
ITMI951649A1 (it) 1997-01-27
RU2211707C2 (ru) 2003-09-10
DE69621022D1 (de) 2002-06-06
EP0841907A1 (en) 1998-05-20
EP0841907B1 (en) 2002-05-02
HK1015698A1 (en) 1999-10-22
CA2224293A1 (en) 1997-02-13
IL122915A0 (en) 1998-08-16
IL122915A (en) 2003-05-29
WO1997004760A1 (en) 1997-02-13
JPH11511126A (ja) 1999-09-28
BR9609856A (pt) 1999-03-16
US20020028790A1 (en) 2002-03-07
DE69621022T2 (de) 2003-02-27
ATE216878T1 (de) 2002-05-15
AU707808B2 (en) 1999-07-22
AU6736696A (en) 1997-02-26
US6326370B1 (en) 2001-12-04
IT1277373B1 (it) 1997-11-10
ES2173307T3 (es) 2002-10-16

Similar Documents

Publication Publication Date Title
NO981477L (no) Pyrimidinderivater som 5HT2C-reseptor antagonister
ITPD910047A0 (it) Strumento per la legatura di emorroidi o simili
PT754407E (pt) Formulacoes liquidas de 1,2-benzisotiazolin-3-ona
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
HUT73670A (en) Use of indole derivatives as 5ht1 antagonists
FI973407A7 (fi) Kirurgin takki
ITMI951649A0 (it) Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato
IT1272922B (it) Procedimento per la preparazione di composti metallocenici
ITMI913465A1 (it) Procedimento per la depurazione dell'1, 1, 1-trifluoro-2-fluoroetano
BR9708595A (pt) Utilização de derivados de 2,5- di-hidroxibenzenossulfonicos
HUP9600517A2 (en) New tricyclic derivatives, their preparation, their use for the preparation of optically active or valemic colchicine and thiocolchine and analogues and derivatives and intermediates
EP1116726A4 (en) Ethylamine derivatives
ITMI941543A0 (it) Procedimento per la purificazione dell'idrossido di magnesio
EP1051974A4 (en) LOTIONS CONTAINING VITAMIN D3 DERIVATIVES
KR930017647U (ko) 장농의 옷걸이봉 고정구
ITMI931371A1 (it) Procedimento per la preparazione dell'erdosteina
IT1282639B1 (it) Dispositivo per l'immagazzinamento di sigarette o simili
ITMI941144A0 (it) Procedimento per la formazione di timbri
IT1284090B1 (it) Procedimento per la preparazione di cefem derivati
ITMI930630A0 (it) Procedimento per la copolimerizzazione dell'etilene
ITMI982242A0 (it) Procedimento per la preparazione di un derivato dell'isobenzofurano
ITMI971894A1 (it) Procedimento per la preparazione di un derivato dell'uridina
IT1295003B1 (it) Composizioni farmaceutiche per il trattamento dell'herpes simplex
ITMI940806A0 (it) Procedimento per la prevenzione della nebbia lungo le strade
ITRM950548A0 (it) Procedimento per la preparazione di ammidi

Legal Events

Date Code Title Description
0001 Granted